Abstract
Objective To investigate the effect of recombinant human interleukin 2 (rh IL-2) on rheumatoid arthritis (RA) combined with Sjogren’s syndrome (SS) and the level of serum B lymphocyte stimulator (Blys). Methods All of 60 cases of SS patients combined with RA in University Hospital of Hubei University for Nationalities from February 2014 to June 2017 were randomly divided into two groups.The treatment group (30 cases) were given rh IL-2 50000 IU daily by subcutaneous injection for 5 days.The control group(30 cases) were given routine anti immunotherapy.The Schirmer test and saliva flow rate were used to evaluate the improvement of patients' SS symptoms.The 28 joint disease activity score(DAS28) and the pressure pain index of the joint swelling were used to evaluate the improvement of the patients' RA symptoms.Enzyme-linked immunosorbent assay(ELISA) was used to detect serum Blys and immune indexes, and the difference was compared before and after treatment. Results The improved difference was respectively 1.51 (95% CI: 0.938-2.082) mm/min in left eyetear flow, 1.67 (95% CI: 1.095-2.245) mm/min in right eye tear flow, and 0.21.(95% CI: 0.049-0.371)mL/min in salivary flow rate after treatment.The Schirmer test and salivary flow rate in the treatment group were better than those in the control group (P 0.05). Conclusion RhIL-2 can alleviate the autoimmune response and improve the clinical symptoms of RA with SS by lowering serum Blys level which has obvious therapeutic effect on RA with SS. Key words: Recombinant human interleukin 2; Rheumatoid arthritis; Sjogren’s syndrome; Serum B lymphocyte stimulator
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
